Godavari Drugs Ltd. Promoter Acquires Convertible Warrants
Godavari Drugs Limited announced that Aksheit Kakani, a Promoter of the Company, has acquired 150,000 Convertible Warrants through a preferential issue on March 18, 2026.According to a filing, prior to the acquisition, Kakani held 326,000 shares representing 4.33% of the company’s total share capital. After acquiring the warrants, Kakani’s total holdings now include 476,000 warrants, representing 3.22% of the company’s share capital.
The preferential allotment involved 150,000 warrants, valued at Rs. 7,53,05,000 divided into 75,30,500 fully paid-up equity shares of Rs. 10 each.
The company's equity share capital prior to the acquisition was Rs. 10,12,74,350, divided into 1,01,27,430 equity shares of Rs. 10 each. Following the acquisition, the total equity share capital stands at Rs. 10,12,74,350, divided into 1,01,27,430 equity shares of Rs. 10 each.
| Disclosures under Regulation 29(2) of SEBI (Substantial Acquisition Regulations, 2011 | of Shares | andTakeovers) | |
|---|---|---|---|
| Details of the acquisition/sate | |||
| c) Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each calegory) acquired/sold | 1.50.000 | 120 | |
| d) Shares encumbered / invoked/released by theacquirer | |||
| After the acquisition/sate (disposal, holding of: | After the acquisition/sate (disposal, holding of: | After the acquisition/sate (disposal, holding of: | |
| Mode of acquisition / sate (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transler etc). | 1,50,000(One LakhFifty Thousand Only) Convertible Warrants by way of preferential Allotment | ||
| Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is | 18" March, 2026 |
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.